Mechanistically, this combination effect is mediated, in part, by the re-activation of TRIM16 expression, previously shown to be a metastasis suppressor in melanomagenesis that can be restored by vemurafenib in BRAFV600 melanoma in vitro and in patients treated with vemurafenib [29]. The gene discussed is TRIM16; the disease is melanoma.